News | Media | Cinclus Pharma

Presentation of the company and the development of linaprazan glurate from Redeye Transactions

14 Jun 2024

Here you can watch the full presentation (in Swedish) of Cinclus Pharma and the development of linaprazan glurate, held by CEO Christer Ahlberg at Redeye Transactions June 13th.

Presentation of the company and the development of linaprazan glurate from Aktiespararnas event June 12th

13 Jun 2024

Here you can watch the full presentation (in Swedish) of Cinclus Pharma and the development of linaprazan glurate, held by CEO Christer Ahlberg at Aktiespararnas event June 12th.

Cinclus Pharma announces listing on Nasdaq Stockholm and offering of ordinary shares as well as publishes related prospectus

10 Jun 2024

Cinclus Pharma Holding AB (publ) (“Cinclus Pharma” or the “Company”), a Swedish clinical stage pharmaceutical company, has resolved to diversify the shareholder base through an offering of newly issued ordinary shares (the “Offering”) and has at the same time applied for listing of the Company’s ordinary shares on Nasdaq Stockholm (the “Listing”). Nasdaq Stockholm’s Listing Committee has resolved to admit the Company’s ordinary shares to trading, subject to the fulfillment of certain customary conditions no later than on the first day of trading. The prospectus relating to the Offering and the Listing, including the price and other terms of the Offering, is published today and the first day of trading is expected to be 20 June 2024.